Digestive and Liver Disease最新文献_第4页

A critical appraisal of the safety and efficacy of P-ESWL in treating pancreatic stones. 对 P-ESWL 治疗胰腺结石的安全性和有效性进行严格评估。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-10-07 DOI: 10.1016/j.dld.2024.09.022

Jianyu Lv, Siyi Ni, Mi Zhou

引用次数: 0

Optimization of surgical evaluation algorithms for living donor liver transplantation. 活体肝移植手术评估算法的优化。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-10-07 DOI: 10.1016/j.dld.2024.09.018

Paul Kupke, Verena Schropp, Leonhard A Schurr, Ivor Dropco, Laura S Kupke, Markus Götz, Edward K Geissler, Hans J Schlitt, Jens M Werner

{"title":"Optimization of surgical evaluation algorithms for living donor liver transplantation.","authors":"Paul Kupke, Verena Schropp, Leonhard A Schurr, Ivor Dropco, Laura S Kupke, Markus Götz, Edward K Geissler, Hans J Schlitt, Jens M Werner","doi":"10.1016/j.dld.2024.09.018","DOIUrl":"https://doi.org/10.1016/j.dld.2024.09.018","url":null,"abstract":"Background: Living donor liver transplantation (LDLT) is an established and endorsed alternative for deceased donor liver transplantation with better recipient outcomes. Nevertheless, while extensive evaluation of potential donors is crucial, evaluation algorithms differ between transplant centres and guidelines.Methods: We included 317 individuals evaluated for LDLT between 07/2007-07/2022 in a retrospective analysis. The evaluation process was analysed to identify the key reasons for declining 77 potential donors. Additionally, 146 donors that underwent LDLT were analysed regarding risk factors for complications.Results: The main reasons for donor refusal were liver volumetry (40.3 %) and metabolic factors including obesity or steatotic liver disease (20.8 %). Contrast-enhanced computed tomography (CECT) identified 63.6 % of all declined donors; CECT combined with assessment of medical history, physical examination, blood testing and ultrasonography, identified 87.0 % of declined potential donors. Associated with this selection, complication rates in donors were low (≥II in 17.1 %; none with ≥IVb). Notably, higher age was a risk factor for developing a complication ≥II after hemi-hepatectomy (p = 0.0373).Conclusions: We propose a progressive 4-step evaluation algorithm that begins with a very basic assessment combined with up-front CECT. This early phase of testing is expected to identify nearly 90 % of ineligible donors, thereby conserving critical resources, time and money, as well as minimising burden for potential donors.Funding: J.M.W. received funding by grant We-4675/6-1 from the Deutsche Forschungsgemeinschaft (DFG) in Bonn, Germany.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fecal calprotectin measurement as a biomarker of severe disease phenotype in celiac disease and non-celiac enteropathies. 粪便钙蛋白检测作为乳糜泻和非乳糜泻性肠病严重疾病表型的生物标志物。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-10-05 DOI: 10.1016/j.dld.2024.09.010

Annalisa Schiepatti, Alessandro Cappellini, Stiliano Maimaris, Paolo Minerba, Martina Retrosi, Giulia Mantica, Chiara Scarcella, Claudia Delogu, Giovanni Arpa, Paola Ilaria Bianchi, Antonio Di Sabatino, Federico Biagi

{"title":"Fecal calprotectin measurement as a biomarker of severe disease phenotype in celiac disease and non-celiac enteropathies.","authors":"Annalisa Schiepatti, Alessandro Cappellini, Stiliano Maimaris, Paolo Minerba, Martina Retrosi, Giulia Mantica, Chiara Scarcella, Claudia Delogu, Giovanni Arpa, Paola Ilaria Bianchi, Antonio Di Sabatino, Federico Biagi","doi":"10.1016/j.dld.2024.09.010","DOIUrl":"10.1016/j.dld.2024.09.010","url":null,"abstract":"Background: Fecal calprotectin (FC) is a non-invasive biomarker of gut inflammation, but its role in celiac disease (CD) and non-celiac enteropathies (NCEs) is undefined.Aims: To retrospectively evaluate FC in patients with CD and NCEs as a tool for assessing disease activity and predicting long-term outcomes.Methods: Patients with uncomplicated and complicated CD, and NCEs with data on FC, evaluated at our center between June-2008 and December-2023, were enrolled. The relationship between elevated FC (>50 mg/kg) and disease activity was statistically analysed and Cox regression adjusted for age and sex was used to compare development of complications and mortality in patients with elevated and normal FC.Results: 177 patients (109F, mean age at diagnosis 39±20 years, 132 CD, 17 complicated CD, 28 NCEs) were enrolled. 55 patients had elevated FC, which was associated with lack of clinical and histological response to therapy (both p < 0.001). During a median follow-up of 103 months (IQR 54-176), 22 patients developed complications (15.4 %) and 21 died (11.9 %). Elevated FC was significantly more common in complicated CD (70.6 %) and NCEs (67.9 %) than in uncomplicated CD (18.2 %), p < 0.001. Elevated FC was independently predictive of developing complications (HR 4.8,95 %CI 1.4-17.7, p = 0.01) and mortality (HR 4.8,95 %CI 1.6-14.3, p < 0.01).Conclusion: FC is a promising non-invasive biomarker for assessing disease severity and long-term outcomes in CD and NCEs.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Computer aided villi morphometric quantification in video-capsule enteroscopy: A newly developed software to quantify small bowel atrophy. 视频胶囊肠镜中的计算机辅助绒毛形态定量：新开发的量化小肠萎缩的软件。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-10-01 DOI: 10.1016/j.dld.2024.09.008

Nicoletta Nandi, Matilde Topa, Alessandro Rimondi, Michele M Ciulla, Gian Eugenio Tontini, Lucia Scaramella, Reena Sidhu, Maurizio Vecchi, Luca Elli

{"title":"Computer aided villi morphometric quantification in video-capsule enteroscopy: A newly developed software to quantify small bowel atrophy.","authors":"Nicoletta Nandi, Matilde Topa, Alessandro Rimondi, Michele M Ciulla, Gian Eugenio Tontini, Lucia Scaramella, Reena Sidhu, Maurizio Vecchi, Luca Elli","doi":"10.1016/j.dld.2024.09.008","DOIUrl":"https://doi.org/10.1016/j.dld.2024.09.008","url":null,"abstract":"Background and aims: Small bowel capsule endoscopy (SBCE) has an established role in patients with non-responsive celiac disease (CeD). A non-invasive method to quantify small bowel atrophy is still lacking.Methods: We analysed SBCE frames from CeD patients from 2018 to 2020. Histology was the reference standard, with atrophy defined as Marsh-Oberhuber score ≥ 3a. Three regions of interest (ROI) were blindly selected from each frame by an expert gastroenterologist and analysed using a National Institute of Health J image-processing software into a numerical scale. A 3D surface plot macro identified intestinal villi density through isolines plots.Results: We acquired 306 ROIs from 57 frames with macroscopic atrophy and 45 with normal mucosa. Frames were classified as atrophic (n = 63) or non-atrophic (n = 39) per Marsh-Oberhuber classification. Median density score significantly differed between atrophic and non-atrophic frames (p < 0.001). The morphometric analysis showed a sensitivity of 77 % and a specificity of 79 % in discriminating between atrophic or non-atrophic mucosa with a 14.10 cut-off (Youden Index) and an overall AUC of 0.805 (CI 95 % 0.712-0.897).Conclusions: Our newly developed SBCE software can effectively quantify villous atrophy. Further studies are needed to validate its applicability in an external cohort.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contrast-enhanced intraoperative ultrasound improved hepatic recurrence-free survival in initially unresectable colorectal cancer liver metastases. 对比增强术中超声提高了最初无法切除的结直肠癌肝转移灶的无肝复发生存率。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-09-29 DOI: 10.1016/j.dld.2024.09.009

HuiFang Li, Ming Shi, Xingzhang Long, Pinzhu Huang, Chuan Peng, Wei He, Yuhong Li, Binkui Li, Yunfei Yuan, JiLiang Qiu, Ruhai Zou

{"title":"Contrast-enhanced intraoperative ultrasound improved hepatic recurrence-free survival in initially unresectable colorectal cancer liver metastases.","authors":"HuiFang Li, Ming Shi, Xingzhang Long, Pinzhu Huang, Chuan Peng, Wei He, Yuhong Li, Binkui Li, Yunfei Yuan, JiLiang Qiu, Ruhai Zou","doi":"10.1016/j.dld.2024.09.009","DOIUrl":"https://doi.org/10.1016/j.dld.2024.09.009","url":null,"abstract":"Background: We aimed to evaluate the role of Contrast-enhanced intraoperative ultrasound (CE-IOUS) with perfluorobutane microbubbles (Sonazoid) in improving the prognosis of patients with unresectable colorectal cancer liver metastases (CRLM).Methods: A total of 130 Patients with unresectable CRLM who underwent curative hepatic resection at our institute were retrospectively analyzed. Of these 130 enrolled patients, 67 underwent intraoperative ultrasound alone (IOUS group); 63 underwent additional CE-IOUS and IOUS (CE-IOUS group). Normalized inverse probability treatment weighting (IPTW) was employed to balance baseline characteristics between groups. Hepatic recurrence-free survival (HRFS) and overall survival (OS) were compared.Results: The treatment strategy was altered in 25 patients (25/63, 39.9%) due to the additional use of CE-IOUS. After applying IPTW, the CE-IOUS group exhibited a significantly lower rate of hepatic recurrence (hazard ratio [HR], 0.55; 95% confidence interval [CI] 0.32-0.95; P = 0.032). Subgroup analysis showed that CE-IOUS provided a significant benefit over IOUS in patients with bilobar liver metastases (P = 0.007), or with a number of live tumors < 3 (P = 0.021), or without DLM (P = 0.018), or with extrahepatic metastasis (P = 0.034), or with a minimum of 6 cycles of systemic therapy (P = 0.03).Conclusions: CE-IOUS is necessary for unresectable CRLM after preoperative chemotherapy, as it enhances detection accuracy and improves the prognosis of unresectable CRLM patients.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis. 代偿期肝硬化患者和大鼠模型的病因特异性炎症模式。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-09-28 DOI: 10.1016/j.dld.2024.09.006

Benedikt Silvester Hofer, Benedikt Simbrunner, Philipp Königshofer, Ksenia Brusilovskaya, Oleksandr Petrenko, Vlad Taru, Thomas Sorz, Kerstin Zinober, Georg Semmler, Stefan G Kauschke, Larissa Pfisterer, Michael Trauner, Mattias Mandorfer, Philipp Schwabl, Thomas Reiberger

{"title":"Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis.","authors":"Benedikt Silvester Hofer, Benedikt Simbrunner, Philipp Königshofer, Ksenia Brusilovskaya, Oleksandr Petrenko, Vlad Taru, Thomas Sorz, Kerstin Zinober, Georg Semmler, Stefan G Kauschke, Larissa Pfisterer, Michael Trauner, Mattias Mandorfer, Philipp Schwabl, Thomas Reiberger","doi":"10.1016/j.dld.2024.09.006","DOIUrl":"https://doi.org/10.1016/j.dld.2024.09.006","url":null,"abstract":"Background: Cirrhosis is associated with a proinflammatory environment.Aims: To analyse aetiology-specific inflammation patterns in compensated cirrhosis in animal models and patients.Methods: Portal pressure (PP), fibrosis (collagen proportionate area [CPA]) and hepatic inflammation were measured in cirrhotic rat models (thioacetamide [TAA;n = 12]; choline-deficient high-fat diet [CDHFD;n = 12]; bile duct ligation [BDL;n = 16]). Compensated cirrhotic patients (alcohol-related liver disease [ALD;n = 67]; metabolic dysfunction-associated steatohepatitis [MASH;n = 50]; cholestatic liver disease [primary biliary cholangitis [PBC]/primary sclerosing cholangitis [PSC];n = 22]) undergoing hepatic venous pressure gradient (HVPG) measurement were included.Results: In rats, hepatic proinflammatory gene expression was highest in CDHFD and lowest in TAA, despite comparable PP levels. Across all animal models, Tnfa/Il6 correlated positively with CPA, and Mcp1 with elevated PP. Mcp1 was also associated with increased CPA in TAA/CDHFD. Mcp1/Cxcl1 showed a model-independent positive correlation to transaminases. Il1b correlated positively with CPA/PP in BDL and with transaminases in CDHFD. In patients, CRP/IL-6 were lower in MASH compared to ALD or PBC/PSC, regardless of hepatic function. IgA/IgG were highest and complement factors lowest in ALD. More pronounced systemic inflammation was linked to higher HVPG primarily in ALD/MASH.Conclusion: Proinflammatory pathways are upregulated across all liver disease aetiologies, yet their association with fibrosis and portal hypertension can vary.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CHEK2 mutation causes manifestations similar to Lynch syndrome and Li-Fraumeni syndrome CHEK2突变会导致类似林奇综合征和李-弗劳米尼综合征的表现。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-09-28 DOI: 10.1016/j.dld.2024.06.027

引用次数: 0

Comment to "Modifiable lifestyle factors, genetic and acquired risk, and the risk of severe liver disease in the UK Biobank cohort (Lifestyle factors and SLD)". 对 "英国生物库队列中可改变的生活方式因素、遗传和后天风险以及严重肝病风险（生活方式因素和严重肝病）"的评论。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-09-26 DOI: 10.1016/j.dld.2024.09.001

Aman Advani, Rohet Kumar, Saad Ahmed

引用次数: 0

Full Title Page /Editorial Board 完整扉页/编辑栏

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-09-25 DOI: 10.1016/S1590-8658(24)00983-6

引用次数: 0

Factors affecting treatment decisions for endoscopically resected low- and high-risk malignant colorectal polyps in a screening setting. 在筛查过程中，影响内镜下切除的低风险和高风险恶性大肠息肉治疗决策的因素。

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2024-09-25 DOI: 10.1016/j.dld.2024.08.057

Orietta Giuliani, Flavia Baldacchini, Lauro Bucchi, Silvia Mancini, Alessandra Ravaioli, Rosa Vattiato, Federica Zamagni, Romano Sassatelli, Omero Triossi, Paolo Trande, Caterina Palmonari, Alessandro Mussetto, Carlo Fabbri, Mauro Giovanardi, Angelo de Padova, Fabio Falcini

{"title":"Factors affecting treatment decisions for endoscopically resected low- and high-risk malignant colorectal polyps in a screening setting.","authors":"Orietta Giuliani, Flavia Baldacchini, Lauro Bucchi, Silvia Mancini, Alessandra Ravaioli, Rosa Vattiato, Federica Zamagni, Romano Sassatelli, Omero Triossi, Paolo Trande, Caterina Palmonari, Alessandro Mussetto, Carlo Fabbri, Mauro Giovanardi, Angelo de Padova, Fabio Falcini","doi":"10.1016/j.dld.2024.08.057","DOIUrl":"https://doi.org/10.1016/j.dld.2024.08.057","url":null,"abstract":"Introduction: The European Guidelines for colorectal cancer screening of 2006 state that only high-risk endoscopically resected malignant colorectal polyps (MCPs), defined as poor/no differentiation or positive resection margins or lymphovascular invasion, require colonic resection.Methods: A multicentre series of 954 patients with screen-detected MCP (northern Italy, 2005-2016, age 50-69) was studied to identify (1) the factors affecting the choice of colonic resection, and (2) the factors associated with deviation from the European Guidelines for low- and high-risk patients. Data analysis was based on multilevel logistic regression models.Results: Five hundred sixty-four (59.1 %) patients underwent colonic resection. The factors significantly associated with surgical referral included: distal and rectal versus proximal tumour site (inverse association); sessile and flat versus pedunculated morphology (direct association); tumour size (direct); moderate/poor versus good differentiation (direct); adenocarcinoma of not otherwise specified type versus adenocarcinoma with a residual adenoma component (direct); positive versus negative resection margins (direct); lymphovascular invasion (direct); and high-grade versus low-grade/absent tumour budding (direct). In low-risk MCPs, tumour budding encouraged strongly the decision for surgery. In high-risk MCPs, a distal/rectal tumour site encouraged the follow-up option.Conclusion: The identification of factors associated with treatment choices other than those currently recommended may help prioritise the clinical questions in the development of future guidelines.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0